PEStore

Growth Equity

Athyrium Capital Management LP

Athyrium Capital Management LP takes minority stakes in growing companies, usually without full control, from New York, USA. It states a focus on healthcare & life sciences.

Disclosed holdings82
Earliest stated investment
HeadquartersNew York, USA
Stated fund size$5B+

Stated investment criteria

What Athyrium Capital Management LP says it buys

Read from Athyrium Capital Management LP’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.

People listed on its team page211

A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. The team figure counts the people the firm shows on one team page, so it is a floor rather than a headcount: firms that split their team across tabs or load it in pages will read low. Nothing here is a commitment by Athyrium Capital Management LP to consider any particular business, and nothing on this page is represented as being for sale.

Regulatory record

How Athyrium Capital Management LP is registered

From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.

Adviser statusSEC registered
Regulatory assets under management$2.5bn
Employees20
Private funds advised8 · $2.5bn gross
SEC adviser numberCRD 161528

Portfolio

Disclosed holdings

Companies Athyrium Capital Management LP lists on its own website. No investment years are published.

CompanyInvestedYears heldRecorded transaction
Agendia
Alcresta
Alvogen
Amagpharma
Amrytpharma
Apolloendo
Aquadermatology
Arisglobal
Azurity
Basf
Basilea Pharmaceutica
Bendbioscience
Bioclinica
Biocryst
Bionpharma
Bioratherapeutics
Bridgebio
Calliditas Therapeutics
Centinelspine
Choice Health At Home
Cipherpharma
Clario
Cloverhealth
Coherus Biosciences
Completehealth
Crown Laboratories
Dermira
Dupagemedicalgroup
Elara
Esperion Therapeutics
Galenica
Gentivahs
Halozyme Therapeutics
Healthsun
Heartlandvetpartners
Hlstherapeutics
Horizon Pharma
Indivior
Innopharmainc
Innovacarehealth
Ironwood Pharmaceuticals
Lannett
Leonmedicalcenters
Longevityhealthplan
Mallinckrodt
Medicrea
Navihealth
Obhg
Omeros Corporation
Optinose
Ouitherapeutics
PTC Therapeutics
Paratekpharma
Pharm Int
Pharmerica
Portola
Puma Biotechnology
RVL Pharmaceuticals
Revance Therapeutics
Securabio
Soundphysicians
Sucampo
Summitbhc
Syncardia
Teamhealth
Teamservices
Tecomet
Teladochealth
Tesarobio
Travere
Triabeauty
Umotif
Universalbiosensors
Unlock Health
Urpt
Usworldmeds
Valneva
Veloxis
Villagemd
Vitahealth
Vivus
Zealandpharma

Compiled from Athyrium Capital Management LP’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.

Valuation context

Transaction values in Healthcare & Life Sciences

What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.

Median consideration$110m
Middle 50%$30m-$318m
Revenue multiple2.8×
EBITDA multiple12.5×

The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.

For owners

Own a healthcare & life sciences business?

The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.

Request a confidential valuation

For investors

Is this Athyrium Capital Management LP?

Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.

Claim or correct this profile

Targeted buyer search

Which hundred of these would actually buy your business?

A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.

See how it works

Comparable investors

Similar mandates

Other growth equity investors active in healthcare & life sciences.